<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11592764</article-id><article-id pub-id-type="pmc">2375104</article-id><article-id pub-id-type="pii">6692025</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>The treatment of advanced renal cell cancer with high-dose oral thalidomide</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stebbing</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Benson</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eisen</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pyle</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Smalley</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bridle</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mak</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sapunar</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ahern</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gore</surname><given-names>M E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology, The Royal Marsden Hospital, London, SW3 6JJ</aff><aff id="aff2"><label>2</label>HEAL Research Department, North Middlesex Hospital, London, N18 1QX</aff><aff id="aff3"><label>3</label>Chelsea and Westminster Hospital, Department of Clinical Neurophysiology, London, SW10 9NH, UK</aff><pub-date pub-type="ppub"><month>09</month><year>2001</year></pub-date><volume>85</volume><issue>7</issue><fpage>953</fpage><lpage>958</lpage><history><date date-type="received"><day>14</day><month>03</month><year>2001</year></date><date date-type="rev-recd"><day>29</day><month>05</month><year>2001</year></date><date date-type="accepted"><day>05</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Thalidomide is reported to suppress levels of several cytokines, angiogenic and growth factors including TNF-&#x003b1;, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). The resulting anti-angiogenic, immunomodulatory and growth suppressive effects form the rationale for investigating thalidomide in the treatment of malignancies. We have evaluated the use of high-dose oral thalidomide (600&#x02008;mg daily) in patients with renal carcinoma. 25 patients (all men; median age, 51 years; range 34&#x02013;76 years) with advanced measurable renal carcinoma, who had either progressed on or were not suitable for immunotherapy, received thalidomide in an escalating schedule up to a maximum dose of 600&#x02008;mg daily. Treatment continued until disease progression or unacceptable toxicity were encountered. 22 patients were assessable for response. 2 patients showed partial responses (9&#x00025;; 95&#x00025; CI: 1&#x02013;29), 7 (32&#x00025;; 95&#x00025; CI: 14&#x02013;55) had stable disease for more than 6 months and a further 5 (23&#x00025;; 95&#x00025; CI: 8&#x02013;45) had stable disease for between 3 and 6 months. We also measured levels of TNF-&#x003b1;, bFGF, VEGF, IL-6 and IL-12 before and during treatment. In patients with SD &#x02265; 3 months or an objective response, a statistically significant decrease in serum TNF-&#x003b1; levels was demonstrated (<italic>P</italic> = 0.05). The commonest toxicities were lethargy (&#x02265; grade II, 10 patients), constipation (&#x02265; grade II, 11 patients) and neuropathy (&#x02265; grade II, 5 patients). Toxicities were of sufficient clinical significance for use of a lower and well tolerated dose of 400&#x02008;mg in currently accruing studies.  &#x000a9; 2001 Cancer Research Campaign<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>thalidomide</kwd><kwd>renal cell carcinoma</kwd></kwd-group></article-meta></front></article>


